JP7098167B2 - ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子 - Google Patents

ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子 Download PDF

Info

Publication number
JP7098167B2
JP7098167B2 JP2019523040A JP2019523040A JP7098167B2 JP 7098167 B2 JP7098167 B2 JP 7098167B2 JP 2019523040 A JP2019523040 A JP 2019523040A JP 2019523040 A JP2019523040 A JP 2019523040A JP 7098167 B2 JP7098167 B2 JP 7098167B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
pharmaceutically acceptable
hydrogen
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019523040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537592A (ja
JP2019537592A5 (OSRAM
Inventor
リンズレイ，クレッグ，ダブリュー．
エンジャーズ，ダレン，ダブリュー．
コーン，ピー．，ジェフリー
ボリンガー，シーン，アール．
エンジャーズ，ジュリー，エル．
Original Assignee
ヴァンダービルト ユニヴァーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァンダービルト ユニヴァーシティ filed Critical ヴァンダービルト ユニヴァーシティ
Publication of JP2019537592A publication Critical patent/JP2019537592A/ja
Publication of JP2019537592A5 publication Critical patent/JP2019537592A5/ja
Application granted granted Critical
Publication of JP7098167B2 publication Critical patent/JP7098167B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019523040A 2016-11-07 2017-11-07 ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子 Active JP7098167B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662418651P 2016-11-07 2016-11-07
US62/418,651 2016-11-07
US201762542621P 2017-08-08 2017-08-08
US62/542,621 2017-08-08
PCT/US2017/060306 WO2018085803A1 (en) 2016-11-07 2017-11-07 Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Publications (3)

Publication Number Publication Date
JP2019537592A JP2019537592A (ja) 2019-12-26
JP2019537592A5 JP2019537592A5 (OSRAM) 2020-12-17
JP7098167B2 true JP7098167B2 (ja) 2022-07-11

Family

ID=62076815

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523040A Active JP7098167B2 (ja) 2016-11-07 2017-11-07 ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子

Country Status (7)

Country Link
US (1) US11008335B2 (OSRAM)
EP (1) EP3534901B1 (OSRAM)
JP (1) JP7098167B2 (OSRAM)
CN (1) CN109890388B (OSRAM)
BR (1) BR112018013882A2 (OSRAM)
MA (1) MA46722A (OSRAM)
WO (1) WO2018085803A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3474846B1 (en) 2016-06-22 2022-11-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
MA46899A (fr) 2016-11-07 2021-04-14 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
JP7099725B2 (ja) 2016-11-07 2022-07-12 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
US12054487B2 (en) 2018-09-04 2024-08-06 Contineum Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
EP4447953A1 (en) 2021-12-13 2024-10-23 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539988A (ja) 2006-06-12 2009-11-19 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルの調節因子として有用なチエノピリミジン
WO2013040534A1 (en) 2011-09-16 2013-03-21 Vanderbilt University Substituted 1h-pyrazolo[3',4',4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulatiors of the muscarinic acetycholine receptor m4

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594001A (en) 1993-04-08 1997-01-14 The Dupont Merck Pharmaceutical Company Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO2001053331A2 (en) 2000-01-24 2001-07-26 Adherex Technologies, Inc. Peptidomimetic modulators of cell adhesion
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
ES2265437T3 (es) 2000-07-27 2007-02-16 Pharmacia Corporation Terapia de combinacion antagonista epoxi-esteroidal de aldosterona y antagonista beta-adrenergico para tratamiento de la insuficiencia cardiaca congestiva.
US7291733B2 (en) 2003-10-10 2007-11-06 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted tricyclic heterocycles and their uses
ES2344007T3 (es) 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
AR049300A1 (es) 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
ATE455777T1 (de) 2004-07-23 2010-02-15 Medicines Co Leipzig Gmbh Substituierte pyridoä3',2':4,5üthienoä3,2- düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü- pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
EP1619196A1 (de) 2004-07-23 2006-01-25 Curacyte Discovery GmbH Substituierte Pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und Pyrido[3',2':4,5]furo[3,2-d]-pyrimidine zur Verwendung als Inhibitoren der PDA-4 und/oder TNF-alpha Freisetzung
EP1807434B1 (en) 2004-10-25 2010-08-25 Eli Lilly And Company Thienopyridines as allosteric potentiators of the m4 muscarinic receptor
ES2259892B1 (es) 2004-11-30 2007-11-01 Laboratorios Almirall S.A. Nuevos derivados de piridotienopirimidina.
ES2259891B1 (es) 2004-11-30 2007-11-01 Laboratorios Almirall S.A. Nuevos derivados de piridotienopirimidina.
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
AR059901A1 (es) 2006-03-20 2008-05-07 Bayer Pharmaceuticals Corp Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares.
US20080021063A1 (en) 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CN101622252B (zh) 2006-12-29 2015-04-22 里格尔制药公司 用作axl抑制剂的取代三唑
US20090105240A1 (en) 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
WO2009151569A2 (en) 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
PL2467387T3 (pl) 2009-08-20 2015-08-31 Karus Therapeutics Ltd Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu
US20110178107A1 (en) 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
CN102892288B (zh) * 2010-02-11 2016-02-24 范德比尔特大学 作为亲代谢性谷氨酸受体4(mGLuR4)变构增效剂的吡唑并吡啶化合物、吡唑并吡嗪化合物、吡唑并吡嘧啶化合物、吡唑并噻吩化合物和吡唑并噻唑化合物，组合物，以及其治疗神经学上的功能失调的方法
WO2012131297A1 (en) 2011-03-28 2012-10-04 Jonathan Bayldon Baell Pyrido [3',2' :4,5] thieno [3, 2-d] pyrimidin- 4 - ylamine derivatives and their therapeutical use
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
EP2793881B1 (en) 2011-12-21 2018-10-31 The Regents of the University of Colorado Anti-cancer compounds targeting ral gtpase
US8697888B2 (en) 2012-01-06 2014-04-15 Vanderbilt University Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors
EP3321257A1 (en) 2012-02-23 2018-05-16 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
US9056875B2 (en) 2012-08-31 2015-06-16 Vanderbilt University Substituted pyrazolo[3′,4′:4,5]thieno[2,3-C]pyridazin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
US20160200733A1 (en) * 2013-08-23 2016-07-14 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
US9637498B2 (en) * 2013-08-23 2017-05-02 Vanderbilt University Substituted thieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
WO2015200619A1 (en) 2014-06-26 2015-12-30 Rodin Therapeutics, Inc. Inhibitors of histone deacetylase
EP3474846B1 (en) 2016-06-22 2022-11-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
JP7099725B2 (ja) 2016-11-07 2022-07-12 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
MA46899A (fr) 2016-11-07 2021-04-14 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539988A (ja) 2006-06-12 2009-11-19 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルの調節因子として有用なチエノピリミジン
WO2013040534A1 (en) 2011-09-16 2013-03-21 Vanderbilt University Substituted 1h-pyrazolo[3',4',4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulatiors of the muscarinic acetycholine receptor m4

Also Published As

Publication number Publication date
JP2019537592A (ja) 2019-12-26
CN109890388A (zh) 2019-06-14
EP3534901A4 (en) 2020-04-22
EP3534901A1 (en) 2019-09-11
MA46722A (fr) 2019-09-11
BR112018013882A2 (pt) 2018-12-18
US11008335B2 (en) 2021-05-18
CN109890388B (zh) 2023-03-28
US20200181166A1 (en) 2020-06-11
WO2018085803A1 (en) 2018-05-11
EP3534901B1 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
JP7038414B2 (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
JP7098167B2 (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
JP7016471B2 (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
EP3416639B1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m1
JP7097623B2 (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
JP7099725B2 (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
US11352344B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
US10899759B2 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor M1
WO2019126559A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
CN110891569A (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
CN111788182A (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
JP2021505581A (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
JP2021505580A (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
US20180086776A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2025129082A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
CN121002031A (zh) 作为毒蕈碱型乙酰胆碱受体m4的正向别构调节剂的吡咯并吡啶衍生物
HK40014595A (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
HK40014595B (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201104

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220614

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220622

R150 Certificate of patent or registration of utility model

Ref document number: 7098167

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250